Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients

• Status: Completed
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: All

Summary

To compare the efficacy of gefitinib versus pemetrexed as second-line chemotherapy for patients with previous treated non-small cell lung cancer

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gachon University Gil Medical Center
• Treatments: Gefitinib; Pemetrexed

Criteria

Inclusion Criteria:

• Cells pathologically diagnosed as histological or radical surgery or radiation therapy is not possible stage IIIB and stage IV non-small-cell lung cancer patients

• second line

• ECOG 0～2

• Patients with normal liver function and renal function

Exclusion Criteria:

• Patients with severe acute infection requiring antibiotic therapy

• Patients who have received treatment in other areas of cancer within 5 years

• During pregnancy and lactation patients